Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Shares of Relay Therapeutics , which makes similar technology to Scorpion for fighting cancer, jumped 22% on Lilly news, ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

The UK-headquartered pharma is buying into a drug discovery platform developed by Boston, US biotech Scorpion Therapeutics, paying $75 million upfront to get the ball rolling on the partnership ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

However, the guidance reduction stems from an up-front payment it made to acquire Scorpion Therapeutics' STX-478 program to treat breast cancer. This is a one-time financial adjustment related to ...